Evidence map›Paper›PMID 28087505›Full record

GuidelineAnnals of the rheumatic diseases2017

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.

Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados and 19 more

3 registry-linked trialsOpen access · bronzeAbstract readPractice GuidelineReview
PubMed Publisher
In one paragraph

Guideline in Annals of the rheumatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 692 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
692citing papers in PubMed, 8 pooled it
150.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03840785 nacompletednot on this mapstarted 2019, after this paper: background citation

Effect of Argentine Tango Protocol on Total Physical Activity in Patients With Chronic Inflammatory Arthritis

TypeinterventionalSponsorUniversity Hospital, Clermont-FerrandRan2019 to 2020Enrolled27ConditionsRheumatoid Arthritis (RA), Spondyloarthritis (SA)ArmsArgentine tango
NCT05504616 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Physical Activity in Axial Spondyloarthritis: Development and Implementation of an Evidence-Based Health Technology Approach to Improve Adherence to Recommended Guidelines

TypeinterventionalSponsorUniversity Health Network, TorontoRan2022 to 2024Enrolled106ConditionsAxial SpondyloarthritisArmsHealth technology-based intervention strategy
NCT05570656 nacompletednot on this mapstarted 2022, after this paper: background citation

Modeling Spinal Mobility in Ankylosing Spondylitis (AS) : Towards New Telekinetic Biomarkers

TypeinterventionalSponsorUniversity Hospital, MontpellierRan2022 to 2023Enrolled40ConditionsAnkylosing SpondylitisArmsXSENS-Awinda
3 · Its place in the literature

Who cites it

692 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,541 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. La Tunisie medicale · 2025
    Guideline
  4. La Tunisie medicale · 2025
    Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Article
  20. Review

632 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 18 institutions in 13 countries.

Désirée van der HeijdeDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-5781-158X
Sofia RamiroDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-8899-9087
Robert LandewéAmsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.
Xenofon BaraliakosRheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany.
Filip Van den BoschDepartment of Rheumatology, Ghent University and Ghent University Hospital, Ghent, Belgium.
Alexandre SeprianoDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0003-1954-0229
Andrea RegelRheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany.
Adrian CiureaDepartment of Rheumatology, University Hospital Zurich, Zurich Switzerland.
Hanne DagfinrudDiakonhjemmet Hospital, Oslo, Norway.
Maxime DougadosParis Descartes University, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
Floris van GaalenDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Pál GéherSemmelweis University, Budapest, Hungary.
Irene van der Horst-BruinsmaDepartment of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands.
Robert D InmanUniversity of Toronto, Toronto, Ontario, Canada.
Merryn JongkeesPatient Research Partner, Amsterdam, The Netherlands.
Uta KiltzRheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany.
Tore K KvienDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Pedro M MachadoCentre for Rheumatology & MRC Centre for Neuromuscular Diseases, University College London, London, UK.
Helena Marzo-OrtegaNIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK.
Anna MoltoParis Descartes University, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
Victoria Navarro-CompànDepartment of Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain.
Salih OzgocmenDivision of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Erciyes University, Kayseri, Turkey.
Fernando M Pimentel-SantosNOVA Medical School, NOVA University of Lisbon, Lisboa, Portugal.
John ReveilleThe University of Texas-Health McGovern Medical School, Dallas, USA.ORCID http://orcid.org/0000-0001-5950-0913
Martin RudwaleitKlinikum Bielefeld, Bielefeld, Germany.
Jochen SieperDepartment of Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany.
Percival Sampaio-BarrosFaculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Dieter WiekEULAR PARE Patient Research Partner and Chair of EULAR PARE, Berlin, Germany.
Jürgen BraunRheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany.
Leiden University Medical Center · NLRheumazentrum Ruhrgebiet · DEDélégation Paris 5 · FRDiakonhjemmet Hospital · NOAmsterdam UMC Location Vrije Universiteit Amsterdam · NLCharité - Universitätsmedizin Berlin · DEErciyes University · TRGhent University · BEGhent University Hospital · BEHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRSemmelweis University · HUThe University of Texas Health Science Center at Houston · USUniversity College London · GBUniversity Hospital of Zurich · CHUniversity of Leeds · GBUniversity of Lisbon · PTUniversity of Toronto · CAZuyderland Medisch Centrum · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009. After a discussion of the results in the steering group and presentation to the task force, overarching principles and recommendations were formulated, and consensus was obtained by informal voting. A total of 5 overarching principles and 13 recommendations were agreed on. The first three recommendations deal with personalised medicine including treatment target and monitoring. Recommendation 4 covers non-pharmacological management. Recommendation 5 describes the central role of non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice drug treatment. Recommendations 6-8 define the rather modest role of analgesics, and disprove glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for axSpA patents with predominant axial involvement. Recommendation 9 refers to biological DMARDs (bDMARDs) including TNFi and IL-17 inhibitors (IL-17i) for patients with high disease activity despite the use (or intolerance/contraindication) of at least two NSAIDs. In addition, they should either have an elevated C reactive protein and/or definite inflammation on MRI and/or radiographic evidence of sacroiliitis. Current practice is to start with a TNFi. Switching to another TNFi or an IL-17i is recommended in case TNFi fails (recommendation 10). Tapering, but not stopping a bDMARD, can be considered in patients in sustained remission (recommendation 11). The final two recommendations (12, 13) deal with surgery and spinal fractures. The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.

Indexed as

AnalgesicsAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsDrug SubstitutionGlucocorticoidsHumansInterleukin-17SpondylarthritisTreatment OutcomeTumor Necrosis Factor-alphaAnalgesicsAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsGlucocorticoidsInterleukin-17Tumor Necrosis Factor-alphaDMARDs (biologic)NSAIDsPhyscial therapySpondyloarthritisTreatment

Identifiers

PMID28087505
OpenAlexW2572897530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.